JP5694782B2 - 肺癌、腺癌及び他の病状のための治療方法及び組成物 - Google Patents
肺癌、腺癌及び他の病状のための治療方法及び組成物 Download PDFInfo
- Publication number
- JP5694782B2 JP5694782B2 JP2010550647A JP2010550647A JP5694782B2 JP 5694782 B2 JP5694782 B2 JP 5694782B2 JP 2010550647 A JP2010550647 A JP 2010550647A JP 2010550647 A JP2010550647 A JP 2010550647A JP 5694782 B2 JP5694782 B2 JP 5694782B2
- Authority
- JP
- Japan
- Prior art keywords
- paclitaxel
- cisplatin
- dithio
- bis
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 77
- 238000000034 method Methods 0.000 title claims description 62
- 208000020816 lung neoplasm Diseases 0.000 title description 106
- 206010058467 Lung neoplasm malignant Diseases 0.000 title description 102
- 201000005202 lung cancer Diseases 0.000 title description 102
- 238000011282 treatment Methods 0.000 title description 20
- 201000005249 lung adenocarcinoma Diseases 0.000 title description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 250
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 237
- 229930012538 Paclitaxel Natural products 0.000 claims description 234
- 229960001592 paclitaxel Drugs 0.000 claims description 234
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 227
- 229960004316 cisplatin Drugs 0.000 claims description 227
- 206010028980 Neoplasm Diseases 0.000 claims description 138
- 201000011510 cancer Diseases 0.000 claims description 106
- 230000004083 survival effect Effects 0.000 claims description 70
- 210000004027 cell Anatomy 0.000 claims description 66
- 238000002512 chemotherapy Methods 0.000 claims description 66
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 63
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 61
- 230000006870 function Effects 0.000 claims description 58
- 150000003839 salts Chemical class 0.000 claims description 46
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical group [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 45
- 230000015572 biosynthetic process Effects 0.000 claims description 44
- 238000003786 synthesis reaction Methods 0.000 claims description 38
- 208000007502 anemia Diseases 0.000 claims description 33
- BYUKOOOZTSTOOH-UHFFFAOYSA-N 2-(2-sulfoethyldisulfanyl)ethanesulfonic acid Chemical compound OS(=O)(=O)CCSSCCS(O)(=O)=O BYUKOOOZTSTOOH-UHFFFAOYSA-N 0.000 claims description 32
- 210000000130 stem cell Anatomy 0.000 claims description 31
- 210000003743 erythrocyte Anatomy 0.000 claims description 27
- 230000000157 blood function Effects 0.000 claims description 26
- 206010061309 Neoplasm progression Diseases 0.000 claims description 23
- 230000010437 erythropoiesis Effects 0.000 claims description 23
- 230000005751 tumor progression Effects 0.000 claims description 23
- 102000003951 Erythropoietin Human genes 0.000 claims description 20
- 108090000394 Erythropoietin Proteins 0.000 claims description 20
- 229940105423 erythropoietin Drugs 0.000 claims description 20
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 20
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 18
- 230000004936 stimulating effect Effects 0.000 claims description 16
- 230000001965 increasing effect Effects 0.000 claims description 15
- -1 respectively Chemical compound 0.000 claims description 14
- 210000004072 lung Anatomy 0.000 claims description 13
- 230000003284 homeostatic effect Effects 0.000 claims description 12
- SDNJNDFHCODQDQ-UHFFFAOYSA-N n-(2-ethylphenyl)-2-[[2-[(2-ethylphenyl)carbamoyl]phenyl]disulfanyl]benzamide Chemical compound CCC1=CC=CC=C1NC(=O)C1=CC=CC=C1SSC1=CC=CC=C1C(=O)NC1=CC=CC=C1CC SDNJNDFHCODQDQ-UHFFFAOYSA-N 0.000 claims description 11
- 230000001766 physiological effect Effects 0.000 claims description 11
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 10
- 230000003405 preventing effect Effects 0.000 claims description 9
- 102000001554 Hemoglobins Human genes 0.000 claims description 8
- 108010054147 Hemoglobins Proteins 0.000 claims description 8
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical class [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 claims description 5
- 238000005534 hematocrit Methods 0.000 claims description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 4
- 150000003863 ammonium salts Chemical class 0.000 claims description 4
- 159000000007 calcium salts Chemical class 0.000 claims description 4
- 159000000003 magnesium salts Chemical class 0.000 claims description 4
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 claims description 4
- 230000001603 reducing effect Effects 0.000 claims description 4
- KBFJUSPXGQWLBO-UHFFFAOYSA-N sodium;2-(2-sulfoethyldisulfanyl)ethanesulfonic acid Chemical compound [Na].[Na].OS(=O)(=O)CCSSCCS(O)(=O)=O KBFJUSPXGQWLBO-UHFFFAOYSA-N 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 3
- 150000002696 manganese Chemical class 0.000 claims description 3
- 238000004820 blood count Methods 0.000 claims description 2
- VAGSTFRHBOIOKV-UHFFFAOYSA-N [Na].[Na].C(C)S(=O)(=O)O Chemical compound [Na].[Na].C(C)S(=O)(=O)O VAGSTFRHBOIOKV-UHFFFAOYSA-N 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 238000009583 bone marrow aspiration Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 158
- 208000009956 adenocarcinoma Diseases 0.000 description 104
- 239000003814 drug Substances 0.000 description 95
- 229940123237 Taxane Drugs 0.000 description 86
- 229940079593 drug Drugs 0.000 description 86
- 229910052697 platinum Inorganic materials 0.000 description 80
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 48
- 238000009522 phase III clinical trial Methods 0.000 description 29
- 239000003795 chemical substances by application Substances 0.000 description 26
- 239000000902 placebo Substances 0.000 description 25
- 229940068196 placebo Drugs 0.000 description 25
- 210000001519 tissue Anatomy 0.000 description 23
- 102000004127 Cytokines Human genes 0.000 description 22
- 108090000695 Cytokines Proteins 0.000 description 22
- 102000029749 Microtubule Human genes 0.000 description 22
- 108091022875 Microtubule Proteins 0.000 description 22
- 210000004688 microtubule Anatomy 0.000 description 22
- 239000002246 antineoplastic agent Substances 0.000 description 19
- KQYGMURBTJPBPQ-UHFFFAOYSA-L disodium;2-(2-sulfonatoethyldisulfanyl)ethanesulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)CCSSCCS([O-])(=O)=O KQYGMURBTJPBPQ-UHFFFAOYSA-L 0.000 description 18
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 18
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 17
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 17
- 210000001185 bone marrow Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 230000000913 erythropoietic effect Effects 0.000 description 16
- 229940127089 cytotoxic agent Drugs 0.000 description 15
- 230000008569 process Effects 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 14
- 229950009278 dimesna Drugs 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 125000000217 alkyl group Chemical group 0.000 description 12
- 229940088597 hormone Drugs 0.000 description 12
- 239000005556 hormone Substances 0.000 description 12
- 230000007246 mechanism Effects 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 206010021143 Hypoxia Diseases 0.000 description 11
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 11
- 102000004243 Tubulin Human genes 0.000 description 11
- 108090000704 Tubulin Proteins 0.000 description 11
- 230000002411 adverse Effects 0.000 description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 11
- 229960003668 docetaxel Drugs 0.000 description 11
- 239000003446 ligand Substances 0.000 description 11
- 210000002540 macrophage Anatomy 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- 229910052760 oxygen Chemical group 0.000 description 11
- 239000001301 oxygen Chemical group 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 230000006907 apoptotic process Effects 0.000 description 10
- 229960004562 carboplatin Drugs 0.000 description 10
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 10
- 231100000433 cytotoxic Toxicity 0.000 description 10
- 230000001472 cytotoxic effect Effects 0.000 description 10
- 230000000670 limiting effect Effects 0.000 description 10
- 229960004635 mesna Drugs 0.000 description 10
- 230000008093 supporting effect Effects 0.000 description 10
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 9
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 229960001756 oxaliplatin Drugs 0.000 description 9
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 102000003886 Glycoproteins Human genes 0.000 description 8
- 108090000288 Glycoproteins Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 210000004907 gland Anatomy 0.000 description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 7
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 210000003924 normoblast Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 6
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229940047120 colony stimulating factors Drugs 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 230000000762 glandular Effects 0.000 description 6
- 230000013632 homeostatic process Effects 0.000 description 6
- 150000004677 hydrates Chemical class 0.000 description 6
- 230000007954 hypoxia Effects 0.000 description 6
- 230000000394 mitotic effect Effects 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229960005399 satraplatin Drugs 0.000 description 6
- 190014017285 satraplatin Chemical compound 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 206010041823 squamous cell carcinoma Diseases 0.000 description 6
- 206010067484 Adverse reaction Diseases 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 5
- 108010020346 Polyglutamic Acid Proteins 0.000 description 5
- 230000006838 adverse reaction Effects 0.000 description 5
- 210000000601 blood cell Anatomy 0.000 description 5
- 230000032823 cell division Effects 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000003394 haemopoietic effect Effects 0.000 description 5
- 229930195733 hydrocarbon Natural products 0.000 description 5
- 150000002430 hydrocarbons Chemical class 0.000 description 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 5
- 208000003849 large cell carcinoma Diseases 0.000 description 5
- 230000010534 mechanism of action Effects 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 150000003058 platinum compounds Chemical class 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 4
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 4
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 229940034982 antineoplastic agent Drugs 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 230000002124 endocrine Effects 0.000 description 4
- 210000003714 granulocyte Anatomy 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 230000001146 hypoxic effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000004005 intermediate erythroblast Anatomy 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 210000005170 neoplastic cell Anatomy 0.000 description 4
- 230000001613 neoplastic effect Effects 0.000 description 4
- 239000012038 nucleophile Substances 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 208000012111 paraneoplastic syndrome Diseases 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 150000003057 platinum Chemical class 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000011593 sulfur Chemical group 0.000 description 4
- 150000004579 taxol derivatives Chemical class 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 description 3
- 206010061623 Adverse drug reaction Diseases 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 230000033616 DNA repair Effects 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 210000003651 basophil Anatomy 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- OVYQSRKFHNKIBM-UHFFFAOYSA-N butanedioic acid Chemical compound OC(=O)CCC(O)=O.OC(=O)CCC(O)=O OVYQSRKFHNKIBM-UHFFFAOYSA-N 0.000 description 3
- 208000035269 cancer or benign tumor Diseases 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 239000000824 cytostatic agent Substances 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 201000010536 head and neck cancer Diseases 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000031146 intracellular signal transduction Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 210000003593 megakaryocyte Anatomy 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 230000011278 mitosis Effects 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 208000013371 ovarian adenocarcinoma Diseases 0.000 description 3
- 201000006588 ovary adenocarcinoma Diseases 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229920002643 polyglutamic acid Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 210000001995 reticulocyte Anatomy 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 description 3
- 125000003396 thiol group Chemical class [H]S* 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 description 2
- YWLXLRUDGLRYDR-ZHPRIASZSA-N 5beta,20-epoxy-1,7beta,10beta,13alpha-tetrahydroxy-9-oxotax-11-ene-2alpha,4alpha-diyl 4-acetate 2-benzoate Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-ZHPRIASZSA-N 0.000 description 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 2
- 108010049386 Aryl Hydrocarbon Receptor Nuclear Translocator Proteins 0.000 description 2
- 102100030907 Aryl hydrocarbon receptor nuclear translocator Human genes 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000037147 Hypercalcaemia Diseases 0.000 description 2
- 208000002682 Hyperkalemia Diseases 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
- 241001116498 Taxus baccata Species 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 229940122803 Vinca alkaloid Drugs 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229940028652 abraxane Drugs 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 229940044684 anti-microtubule agent Drugs 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000005773 cancer-related death Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000000925 erythroid effect Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000008713 feedback mechanism Effects 0.000 description 2
- 230000008175 fetal development Effects 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 102000018511 hepcidin Human genes 0.000 description 2
- 108060003558 hepcidin Proteins 0.000 description 2
- 229940066919 hepcidin Drugs 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000033444 hydroxylation Effects 0.000 description 2
- 238000005805 hydroxylation reaction Methods 0.000 description 2
- 230000000148 hypercalcaemia Effects 0.000 description 2
- 208000030915 hypercalcemia disease Diseases 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 210000002894 multi-fate stem cell Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 230000020520 nucleotide-excision repair Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000003076 paracrine Effects 0.000 description 2
- 210000004197 pelvis Anatomy 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 150000003385 sodium Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000001562 sternum Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 210000002444 unipotent stem cell Anatomy 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 210000001325 yolk sac Anatomy 0.000 description 2
- JIDDDPVQQUHACU-YFKPBYRVSA-N (2s)-pyrrolidine-2-carbaldehyde Chemical group O=C[C@@H]1CCCN1 JIDDDPVQQUHACU-YFKPBYRVSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- QJKNWVUQWOQIMO-WNQIDUERSA-N 2-amino-5-[[1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid;(2r)-2-amino-3-sulfanylpropanoic acid Chemical compound SC[C@H](N)C(O)=O.OC(=O)C(N)CCC(=O)NC(CS)C(=O)NCC(O)=O QJKNWVUQWOQIMO-WNQIDUERSA-N 0.000 description 1
- OVMSOCFBDVBLFW-VHLOTGQHSA-N 5beta,20-epoxy-1,7beta,13alpha-trihydroxy-9-oxotax-11-ene-2alpha,4alpha,10beta-triyl 4,10-diacetate 2-benzoate Chemical class O([C@@H]1[C@@]2(C[C@H](O)C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)O)C(=O)C1=CC=CC=C1 OVMSOCFBDVBLFW-VHLOTGQHSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 206010003598 Atelectasis Diseases 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108700012439 CA9 Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 1
- 208000006017 Cardiac Tamponade Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010075944 Erythropoietin Receptors Proteins 0.000 description 1
- 102100036509 Erythropoietin receptor Human genes 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- 108010054017 Granulocyte Colony-Stimulating Factor Receptors Proteins 0.000 description 1
- 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 description 1
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 1
- 101000583175 Homo sapiens Prolactin-inducible protein Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 208000016495 Horner Syndrome Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020877 Hypertrophic osteoarthropathy Diseases 0.000 description 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 1
- 206010073059 Malignant neoplasm of unknown primary site Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102000008763 Neurofilament Proteins Human genes 0.000 description 1
- 108010088373 Neurofilament Proteins Proteins 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010074074 Oesophageal compression Diseases 0.000 description 1
- 201000010630 Pancoast tumor Diseases 0.000 description 1
- 208000015330 Pancoast tumour Diseases 0.000 description 1
- 208000001300 Perinatal Death Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010064964 Phrenic nerve paralysis Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102100030350 Prolactin-inducible protein Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 102000013674 S-100 Human genes 0.000 description 1
- 108700021018 S100 Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 102100035726 Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial Human genes 0.000 description 1
- 241000202349 Taxus brevifolia Species 0.000 description 1
- 235000009065 Taxus cuspidata Nutrition 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108010057966 Thyroid Nuclear Factor 1 Proteins 0.000 description 1
- 102000002658 Thyroid Nuclear Factor 1 Human genes 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 208000035134 Trousseau syndrome Diseases 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- KGXGIPRRDQWVET-CBJMTSFPSA-N [(2r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] [(2r,3s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl hydrogen phosphate Chemical class C1=NC(C(N=C(N)N2)=O)=C2N1[C@H](O[C@@H]1CO)CC1OP(O)(=O)OC[C@@H](O1)[C@@H](O)C[C@@H]1N1C=NC2=C1NC(N)=NC2=O KGXGIPRRDQWVET-CBJMTSFPSA-N 0.000 description 1
- IGWMPTNCTVHTOF-UHFFFAOYSA-M [Pt]O Chemical compound [Pt]O IGWMPTNCTVHTOF-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 235000016127 added sugars Nutrition 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical class C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001946 anti-microtubular Effects 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 239000013059 antihormonal agent Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 210000003461 brachial plexus Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 210000004718 centriole Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- CCQPAEQGAVNNIA-UHFFFAOYSA-N cyclobutane-1,1-dicarboxylic acid Chemical group OC(=O)C1(C(O)=O)CCC1 CCQPAEQGAVNNIA-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- HCGVHZGSMKEALA-LSUSWQKBSA-N dApdG Chemical class C1=NC2=C(N)N=CN=C2N1[C@H](O[C@@H]1CO)C[C@@H]1OP(O)(=O)OC[C@@H](O1)[C@@H](O)C[C@@H]1N1C=NC2=C1NC(N)=NC2=O HCGVHZGSMKEALA-LSUSWQKBSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 239000002898 ectopic hormone Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 210000004891 granulocyte-monocyte colony-forming unit Anatomy 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 201000000079 gynecomastia Diseases 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 101150034151 hif-1 gene Proteins 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000008810 intracellular oxidative stress Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015179 malignant superior sulcus neoplasm Diseases 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000011645 metastatic carcinoma Diseases 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000011144 microtubule bundle formation Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 210000005044 neurofilament Anatomy 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229960003552 other antineoplastic agent in atc Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 108700027936 paclitaxel poliglumex Proteins 0.000 description 1
- 229940124583 pain medication Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 238000005222 photoaffinity labeling Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- NDBYXKQCPYUOMI-UHFFFAOYSA-N platinum(4+) Chemical compound [Pt+4] NDBYXKQCPYUOMI-UHFFFAOYSA-N 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 239000002718 pyrimidine nucleoside Substances 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000013120 recombinational repair Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 101150108347 sdhB gene Proteins 0.000 description 1
- 101150114996 sdhd gene Proteins 0.000 description 1
- 208000002034 secondary hypertrophic osteoarthropathy Diseases 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 238000009751 slip forming Methods 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 201000007363 trachea carcinoma Diseases 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002620 vena cava superior Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- ZPUHVPYXSITYDI-HEUWMMRCSA-N xyotax Chemical compound OC(=O)[C@@H](N)CCC(O)=O.O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 ZPUHVPYXSITYDI-HEUWMMRCSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2008/003405 WO2009113983A1 (en) | 2008-03-14 | 2008-03-14 | Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011514355A JP2011514355A (ja) | 2011-05-06 |
| JP2011514355A5 JP2011514355A5 (OSRAM) | 2011-06-16 |
| JP5694782B2 true JP5694782B2 (ja) | 2015-04-01 |
Family
ID=41065492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010550647A Active JP5694782B2 (ja) | 2008-03-14 | 2008-03-14 | 肺癌、腺癌及び他の病状のための治療方法及び組成物 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP2249825B1 (OSRAM) |
| JP (1) | JP5694782B2 (OSRAM) |
| AU (1) | AU2008352597B2 (OSRAM) |
| CA (1) | CA2717181C (OSRAM) |
| DK (1) | DK2249825T3 (OSRAM) |
| WO (1) | WO2009113983A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11471431B2 (en) * | 2010-09-16 | 2022-10-18 | Lantern Pharma Inc. | Increasing cancer patient survival time by administration of dithio-containing compounds |
| CN109619552A (zh) * | 2018-12-05 | 2019-04-16 | 贾志丹 | 适用于肿瘤患者的营养治疗型配方及制备方法、用途 |
| SG11202109705YA (en) * | 2019-03-08 | 2021-10-28 | Lantern Pharma Inc | Method for treating female non-smokers with non-small cell lung cancer |
| CN115040549A (zh) * | 2022-06-07 | 2022-09-13 | 广东特芯生物科技有限公司 | 一种用于肿瘤的组合物 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4177263A (en) | 1972-02-28 | 1979-12-04 | Research Corporation | Anti-animal tumor method |
| US4657927A (en) | 1978-05-04 | 1987-04-14 | Research Corporation | Malonato platinum compounds |
| US4310515A (en) | 1978-05-30 | 1982-01-12 | Bristol-Myers Company | Pharmaceutical compositions of cisplatin |
| US4302446A (en) | 1979-10-02 | 1981-11-24 | Bristol-Myers Company | Pharmaceutical compositions |
| US4451447A (en) | 1980-03-31 | 1984-05-29 | Bristol-Myers Company | Pharmaceutical formulations |
| FR2601675B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US4915956A (en) | 1987-12-16 | 1990-04-10 | Lyphomed, Inc. | Liquid cisplatin formulations |
| US5698582A (en) | 1991-07-08 | 1997-12-16 | Rhone-Poulenc Rorer S.A. | Compositions containing taxane derivatives |
| US5714512A (en) | 1991-07-08 | 1998-02-03 | Rhone-Poulenc Rorer, S.A. | Compositions containing taxane derivatives |
| JPH0776230B2 (ja) | 1992-01-13 | 1995-08-16 | 田中貴金属工業株式会社 | 白金化合物の製造方法 |
| JP2673331B2 (ja) | 1993-01-12 | 1997-11-05 | 田中貴金属工業 株式会社 | 光学的に高純度なシス―オキザラート（トランス―１―１，２―シクロヘキサンジアミン）白金（▲ｉｉ▼） |
| CA2086874E (en) | 1992-08-03 | 2000-01-04 | Renzo Mauro Canetta | Methods for administration of taxol |
| FR2698543B1 (fr) | 1992-12-02 | 1994-12-30 | Rhone Poulenc Rorer Sa | Nouvelles compositions à base de taxoides. |
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| JP3025602B2 (ja) | 1993-05-21 | 2000-03-27 | デビオファーム エス．アー． | 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法 |
| DE69519300T2 (de) | 1994-08-08 | 2001-05-31 | Debiopharm S.A., Lausanne | Stabiles arzneimittel enthaltend oxaliplatin |
| US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| US5789000A (en) * | 1994-11-14 | 1998-08-04 | Bionumerik Pharmaceuticals, Inc. | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum |
| DE19617802A1 (de) | 1996-05-03 | 1997-11-06 | Basf Ag | Verfahren zur heterogen katalysierten Herstellung von Hydroxyalkyl-substituierten Aminoalkinen |
| ES2170414T3 (es) * | 1996-09-23 | 2002-08-01 | Bionumerik Pharmaceuticals Inc | Reduccion de efectos toxicos del carboplatino usando ditioeteres. |
| US6037336A (en) | 1996-09-23 | 2000-03-14 | Bionumerik Pharmaceuticals, Inc. | Reducing toxic effects of carboplatin using dithioethers |
| US6160167A (en) | 1998-04-21 | 2000-12-12 | Bionumerik Pharmaceuticals, Inc. | Mercaptans and disulfides |
| JP2004523518A (ja) * | 2001-01-19 | 2004-08-05 | バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド | より効能が大きく副作用の少ない癌治療方法 |
| US8710095B2 (en) * | 2002-04-30 | 2014-04-29 | Bionumerik Pharmaceuticals, Inc. | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity |
| US6504049B1 (en) | 2002-04-30 | 2003-01-07 | Bionumerik Pharmaceuticals, Inc. | Process for synthesizing pharmaceutically active disulfide salts |
| US20050256055A1 (en) | 2004-05-12 | 2005-11-17 | Hausheer Frederick H | Compounds and methods for reducing undesired toxicity of chemotherapeutic agents |
| CN101442998B (zh) * | 2006-03-16 | 2012-03-14 | 比奥纽默里克药物公司 | 抗癌活性加强化合物和制剂及其用法 |
| JP6516187B2 (ja) | 2015-07-23 | 2019-05-22 | パナソニックＩｐマネジメント株式会社 | 眠気判定装置、眠気判定方法、眠気判定プログラムおよび記録媒体 |
-
2008
- 2008-03-14 EP EP08726839.7A patent/EP2249825B1/en active Active
- 2008-03-14 WO PCT/US2008/003405 patent/WO2009113983A1/en not_active Ceased
- 2008-03-14 DK DK08726839.7T patent/DK2249825T3/en active
- 2008-03-14 AU AU2008352597A patent/AU2008352597B2/en active Active
- 2008-03-14 CA CA2717181A patent/CA2717181C/en active Active
- 2008-03-14 JP JP2010550647A patent/JP5694782B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2249825B1 (en) | 2015-10-07 |
| EP2249825A1 (en) | 2010-11-17 |
| JP2011514355A (ja) | 2011-05-06 |
| DK2249825T3 (en) | 2016-01-11 |
| CA2717181C (en) | 2013-10-15 |
| AU2008352597B2 (en) | 2012-03-08 |
| WO2009113983A1 (en) | 2009-09-17 |
| EP2249825A4 (en) | 2011-10-05 |
| CA2717181A1 (en) | 2009-09-17 |
| AU2008352597A1 (en) | 2009-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7564119B2 (ja) | ナルトレキソン及びカンナビノイドを含む癌の治療 | |
| JP7193591B2 (ja) | 化学療法の改善 | |
| US20120294957A1 (en) | Treatment of lung cancer | |
| JP5667886B2 (ja) | 癌患者の生存時間を増大させるための組成物及び化合物の使用方法 | |
| Wu et al. | Quercetin induced NUPR1-dependent autophagic cell death by disturbing reactive oxygen species homeostasis in osteosarcoma cells | |
| JPWO2015178426A1 (ja) | がん幹細胞の増殖抑制剤 | |
| TW202028182A (zh) | 用於癌症治療之免疫調節之組合 | |
| JP5694782B2 (ja) | 肺癌、腺癌及び他の病状のための治療方法及び組成物 | |
| Harada et al. | Paclitaxel in combination with cetuximab exerts antitumor effect by suppressing NF-κB activity in human oral squamous cell carcinoma cell lines | |
| US20090232906A1 (en) | Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions | |
| US20230210794A1 (en) | Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds | |
| AU2010224108A1 (en) | Treatment of pancreatic cancer | |
| TW202106292A (zh) | 難治性癌症之預防或治療用之醫藥組合物 | |
| JP2019520310A (ja) | 癌及び前癌病変に対する治療剤、治療方法、及び治療薬剤製造方法 | |
| CA3017557A1 (en) | Combination therapy for proliferative diseases | |
| RU2678103C2 (ru) | Противоопухолевое средство, содержащее противоопухолевый комплекс платины, и усилитель противоопухолевого эффекта | |
| JP2014221752A (ja) | ガン幹細胞に対する分化促進薬及び脳腫瘍治療薬 | |
| CN104606189B (zh) | 一种化合物在制备mTOR抑制剂中的应用 | |
| JP2022528454A (ja) | Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用 | |
| JP2023536389A (ja) | ペンタアザ大環状環複合体およびホルモン療法剤の併用がん治療法 | |
| JP6488280B2 (ja) | タキサン系化合物を含有する抗腫瘍剤及び抗腫瘍効果増強剤 | |
| AU2010336256A1 (en) | Antitumor Agent or Postoperative Adjuvant Chemotherapeutic Agent for Hepatocellular Carcinoma Treatment | |
| WO2024186961A1 (en) | Mitochondria-targeted agents for disease prevention and treatment | |
| WO2020229685A1 (en) | Combination therapy for proliferative conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110304 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110304 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130423 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130717 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130724 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131017 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140527 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140814 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140821 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141126 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150113 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150205 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5694782 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |